Here are four quick facts:
1. Two analysts granted the shares a “buy” rating.
2. One analyst gave the shares an “outperform” rating, and another analyst gave the shares a “underperform” rating.
3. In August 2015, Jefferies analysts reiterated Orthofix International shares’ “buy” rating.
4. Jefferies has a $48 price target on Orthofix stock.
More articles on devices:
CTL Medical Corporation acquires nationally recognized medical device company, AccelSPINE
BionX Medical Technologies raises $17M in series E funding: 4 things to know
Stryker names Gary Boehnlein next VP, CFO — 5 key notes
